Metrion Biosciences Limited (“Metrion”), the dedicated ion channel and cardiac safety screening contract research organization (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the worldwide leader in small molecule and early drug discovery services, announced that Metrion has expanded its High Throughput Screening (HTS) services to incorporate access to Enamine’s compound libraries.
The enamine compound library collection is the most important on this planet and includes each CNS and ion channel-focused goal libraries. The libraries will be divided into individual screening sets, allowing greater flexibility and efficiency in screening and goal identification. Moreover, analog-by-catalog from stock Enamine and make-on-demand REAL libraries provide a rapid and economical solution for hit expansion and structure-activity relationship (SAR) studies.
To make sure diversity and cost-effectiveness, researchers can draw on expert advice from Metrion’s team of ion channel and HTS experts to find out essentially the most effective approach. The corporate may also provide a structured data file of all libraries for comparison with existing libraries, further increasing efficiency.
Metrion’s HTS capabilities were launched in November 2022 as an addition to its extensive preclinical ion channel drug discovery and safety pharmacology services to enhance the corporate’s automated and traditional electrophysiology services. Metrion’s HTS capabilities include screening 384 wells via the FLIPR Penta and Qube-384 systems. The Services provide significant additional capability and adaptability to support ion channel drug discovery projects for the Company’s global customer base.
By combining our specialized ion channel expertise with extensive HTS and hit-finding experience, customers gain access to a dedicated team of drug discovery scientists, ensuring the correct strategic decisions are made within the compounds chosen for screening. This extra access to Enamine’s highest quality screening libraries increases diversity and allows Metrion to maximise research and development budgets much more effectively.
Gary Clark, Director of Screening Technologies, Metrion Biosciences
Enamine is targeted on providing novel chemical compounds to support drug discovery. We’re pleased that Metrion is expanding its HTS service offering to incorporate access to our libraries. Enamine can also be in a position to support subsequent steps of the invention process, including post-delivery of hits, analogization from our stock and on-demand REAL libraries, and custom synthesis of advanced hits and leads.
Vladimir Ivanov, Executive Vice President, Enamine
